The Department of Molecular & Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Pharmacogenomics. 2012 Mar;13(4):399-405. doi: 10.2217/pgs.11.165.
An association between carbamazepine-induced hypersensitivity and HLA-A3101 has been reported in populations of both European and Asian descent. We aimed to investigate HLA-A3101 and other common variants across the genome as markers for cutaneous adverse drug reactions (cADRs) attributed to lamotrigine and phenytoin.
MATERIALS & METHODS: We recruited patients with lamotrigine-induced cADRs (n = 46) and patients with phenytoin-cADRs (n = 44) and the 1958 British birth cohort was used as a control (n = 1296). HLA-A*3101 was imputed from genome-wide association study data. We applied genome-wide association to study lamotrigine- and phenytoin-induced cADR, and total cADR cases combined.
Neither HLA-A*3101 nor any other genetic marker significantly predicted lamotrigine- or phenytoin-induced cADRs.
HLA-A3101 does not appear to be a predictor for lamotrigine- and phenytoin-induced cADRs in Europeans. Our genome-wide association study results do not support the existence of a clinically relevant common variant for the development of lamotrigine- or phenytoin-induced cADRs. As a predictive marker, HLA-A3101 appears to be specific for carbamazepine-induced cADRs.
在欧洲和亚洲人群中均报道了卡马西平诱导的过敏反应与 HLA-A3101 之间存在关联。我们旨在研究 HLA-A3101 及基因组中其他常见变异作为与拉莫三嗪和苯妥英相关的皮肤不良反应(cADR)的标志物。
我们招募了拉莫三嗪诱导的 cADR 患者(n=46)和苯妥英诱导的 cADR 患者(n=44),并使用 1958 年英国出生队列作为对照(n=1296)。HLA-A*3101 从全基因组关联研究数据中推断得出。我们应用全基因组关联研究来研究拉莫三嗪和苯妥英诱导的 cADR,以及合并的所有 cADR 病例。
既非 HLA-A*3101 也非任何其他遗传标记可显著预测拉莫三嗪或苯妥英诱导的 cADR。
HLA-A3101 似乎不是欧洲人拉莫三嗪和苯妥英诱导的 cADR 的预测因子。我们的全基因组关联研究结果不支持存在与拉莫三嗪或苯妥英诱导的 cADR 相关的具有临床意义的常见变异。作为预测标志物,HLA-A3101 似乎对卡马西平诱导的 cADR 具有特异性。